PubMed · 1990 · 92 citations · 24 references
MedicineOncologyPathologyBreast OncologyMolecular PathologyNeoplasiaBreast Cancer OncologyBreast CytologyBreast PathologyDuctal Carcinoma In SituMammary TumorsMalignant Breast TumorsVimentin Expression
Vimentin expression in tumors from 83 node-negative and 112 node-positive patients with infiltrative ductal not otherwise specified (NOS) breast carcinomas has been compared with 5-year survival. For node-negative, but not for node-positive patients, there was a significant inverse relation between vimentin expression and survival. Five-year survival of node-negative patients with vimentin-positive tumors was significantly worse compared with vimentin-negative tumors (P less than 0.0001). In the node-negative group, only 36% of patients with vimentin-positive tumors but 82% of patients with vimentin-negative tumors survived 5 years. Tumors of all eight node-negative patients with ductal NOS cancer who died in the first 27 months expressed vimentin. Multivariate analysis of the node-negative group showed a strong correlation of vimentin expression and overall survival, but weak and not significant correlation between histologic grade or size and overall survival at 5 years. Thus vimentin expression seems to be a strong indicator of poor prognosis in node-negative ductal NOS breast carcinomas.
24
Histological Grading and Prognosis in Breast Cancer
H. J. G. Bloom, W Richardson · British Journal of Cancer · 1957 · 2.9K citations · Full text
The value of estrogen and progesterone receptors in the treatment of breast cancer
C. Kent Osborne, Michael G. Yochmowitz, William A. Knight et al. · Cancer · 1980 · 725 citations · Full text
Medicine, Endocrinology, Oncology +17
Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.
C Wright, Brian Angus, S Nicholson et al. · PubMed · 1989 · 587 citations
Monoclonal antibodies specific for vimentin.
Mary Osborn, E. Debus, K. Weber · PubMed · 1984 · 395 citations